XIROMED
GenericsXIROMED is a generic drug manufacturer focused on Oncology, Dermatology, Cardiovascular.
XIROMED's Key Drugs
XIROMED's core commercial portfolio centers on LORYNA, SYEDA, ESTARYLLA, spanning Oncology and Dermatology — its most strategically important drugs approved in the last 15 years.
XIROMED's Recent FDA Approvals
New NDA/BLA approvals for XIROMED over the last two years — novel drugs only, excluding generics and label supplements.
XIROMED's Therapeutic Areas
XIROMED's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
XIROMED's Top Competitors
XIROMED's closest competitors by therapeutic-area and drug-target overlap include Baxter, Merck, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
XIROMED Pipeline Snapshot
Active clinical trials for XIROMED across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LORYNA leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (14)
Discontinued (2)
Company Info
- First Approval
- 2010-08-03
- Latest
- 2026-06-16
- Applications
- 86